×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
How Medical Writing Can Support Accelerating the Development of Rare Disease Therapies: Insights from the FDA’s START Program Pilot
Session Chair(s)
Robin Whitsell
President
Whitsell Innovations, Inc., United States
This session will explore the FDA START program for accelerating rare disease therapies. We will invite companies who participated in the START pilot and a FDA representative.
Learning Objective : Explain the objectives of the FDA START Program and its role in supporting rare disease development; Detail how medical writers can support companies applying for and participating in the START program; Provide an update on the progress of the pilot.
Speaker(s)
Panelist
Madiha Khalid
Larimar Therapeutics, United States
Senior Director of Medical Writing
Panelist
Jhon Cores
Moderna, United States
Associate Director, Medical Writing
Have an account?